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ABSTRACT 
Luminescent semiconductor quantum dots (QDs) have recently been used for 
delivering and monitoring biomolecules, such as drugs and proteins. However, QDs alone 
have a very low efficiency of transport across the plasma membrane. In order to increase 
the efficiency of QD delivery, synthetic nona-arginine (sR9) was used, a cell penetrating 
peptide, to facilitate uptake. Data demonstrated that sR9 could significantly increase the 
cellular uptake of QDs by noncovalent binding between QDs and sR9. Furthermore, the 
mechanisms of QD/sR9 cellular internalization were investigated. Low temperature and 
metabolic inhibitors markedly inhibited the uptake of QD/sR9, indicating that 
internalization is an energy-dependent process. Several pathway inhibitors and the RNAi 
technique were used to analyze the mechanism of uptake in live cell imaging studies. 
siRNA knockdown demonstrated that clathrin-, and caveolin-dependent endocytosis were 
not involved in QD/sR9 internalization. The conclusion is that the major routes of cellular 
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 1. INTRODUCTION 
Fluorescent semiconductor quantum dots (QDs) have been used to deliver and 
monitor biomolecules into cells in the past few years (Hoshino et al., 2004; Bharali et al., 
2005; Michalet et al., 2005). Advantages of QDs over traditional dyes and proteins (e.g., 
GFP, RFP) include, but are not limited to, their unique physical and chemical properties 
such as photostability, high quantum yield, narrow emission peak, exceptional resistance 
to degradation, and broad size-dependent photoluminescence (Alivisatos et al., 2005; 
Michalet et al., 2005). QDs properties such as multiplexing potential, photostability, and 
inorganic nature make them useful for delivering or monitoring biomolecules in live cells. 
However, although QDs could be engulfed into living cells, the intracellular 
concentration of QDs is not very high (Xue et al., 2007). Therefore, recently bio-
conjugates or peptide-mediated QDs delivery were carried out to improve the 
internalization.    
Cell penetrating peptides (CPPs), also known as protein transduction domains 
(PTDs) or membrane transduction peptides (MTPs), have been used for transduction of 
biologically active proteins, siRNA, and drugs across plasma membranes (Dietz and Bahr 
2004; Wang et al., 2007). The advantages of CPPs include ease of preparation, lack of 
toxicity to the cell, and high efficiency of transduction (Tunnemann et al., 2008). CPPs 
can enter cells in a half-time of 1.8 minutes, corresponding to a first-order rate constant k 
of 0.007 sec-1 (Ziegler et al., 2005). Among many CPPs, the cellular uptake of 
polyarginine tends to be more efficient than that of polylysine, polyhistidine or 
polyornithine (Futaki, 2002). The highest translocation efficiency was reached by using 
octa-arginine or nona-arginine peptides (Futaki, 2002). sR9 has been shown to effectively 
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deliver not only covalently fused protein but also noncovalent mixed protein into 
different types of animal and plant cells (Wang et al., 2006; Wang et al., 2007).   
The exact mechanism of cellular entry of CPPs is still under vigorous debate. 
Several reports previously showed that CPPs delivery of molecules into cells was 
independent of endocytosis, energy, receptors, or active transporters (Schwarze et al., 
2000; Lindsay, 2002; Wadia and Dowdy, 2002). Later, it was found that fixing cells 
might have artificially transduced molecules across plasma membranes. More recent 
studies with live cell imaging suggested the mechanisms may involve macropinocytosis 
(Snyder and Dowdy, 2004; Chang et al., 2007).   
The uptake mechanism of QDs is less-well studied. By using specific inhibitors, 
Ruan et al. identified macropinocytosis, actin filaments, and microtubules as required for 
of internalization and intracellular transport for streptavidin-coated QD/Tat-biotin in 
HeLa cells (Ruan et al., 2007). Zhang et al. demonstrated that carboxylic QDs were 
internalized by lipid rafts dependent endocytosis in human epidermal keratinocytes 
(HEKs), and these pathways were primarily regulated by the G-protein–coupled receptor 
associated pathway and low density lipoprotein receptor/scavenger receptor (Zhang and 
Monteiro-Riviere, 2009). 
Our goals are to 1) test whether synthetic nona-arginine (sR9) can noncovalently 
facilitate QD uptake and 2) investigate the internalization mechanism of QD/sR9.  We 
treated A549 cells with QDs alone and QD/sR9 complex, respectively, to demonstrate the 
efficiency uptake of QDs at the aid of sR9. Inhibitors and siRNA were used to study 
mechanism of uptake. 
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2. REVIEW OF LITATURE 
2.1. INTRODUCTION OF QUANTUM DOTS 
Quantum dots are colloidal nanocrystals with unique optical properties that make 
them outstanding fluorescent probes for long-term and multicolor imaging.  
2.1.1. QD Anatomy. QDs consist of a semiconductor core, a passivation shell 
(usually made of ZnS), and additional coatings. The core is composed of periodic groups 
of II–VI (e.g. CdSe, CdTe, CdS, ZnSe), III–V (e.g. InP, InAs) or IV–VI (e.g. PbSe) 
(Figure 2.1). The size of the core is 2 to 10 nm. Figure 2.2 shows the size comparison of 
QDs and comparable objects. The size of QDs can increase dramatically depending on 
the coating layer around the core. A thin layer of ZnS on the nanoparticle surface protects 
the core from oxidation and increases the photoluminescence quantum yield (Michalet et 
al., 2005; Maysinger et al., 2007). The charge of the nanoparticles is determined by polar 
groups of the coating ligands and the surrounding pH. 
QDs are mostly synthesized in nonpolar organic solvents, which make them 
insoluble in water. Their hydrophobic surface ligands must be replaced by hydrophilic 
ones for biological applications. QDs can also be prepared by water-based synthesis 








(Maysinger et al., 2007) 
Figure 2.1. Anatomy of QDs. Surface modifications of QDs provide protection of the 





(Michalet et al., 2005) 
Figure 2.2. Size comparison of QDs and comparable objects. FITC, fluorescein 
isothiocyanate; GFP, green fluorescent protein; qdot, green (4 nm, top) and red (6.5 nm, 
bottom) CdSe/ZnS qdot; qrod, rod-shaped qdot (size from Quantum Dot Corp.’s Web 
site). Three proteins—streptavidin (SAV), maltose binding protein (MBP), and 





2.1.2. Optical Properties. QDs have some unique optical properties, which make 
them to be a much better imaging tool for delivering and monitoring biomolecules into 
living cells.   
2.1.2.1. Quantum dots have composition- and size-dependent absorption and 
emission. QDs exhibit discrete size-dependent energy levels. As the size of the QDs 
increases, the energy gap also increases, yielding a size-dependent rainbow of colors. The 
color of QDs can be tunable, from ultraviolet to infrared, via varying the size and the 
composition of QDs (Alivisatos et al., 2005; Michalet et al., 2005) (Figure 2.3).  
 
 
(Bruchez et al., 1998) 
Figure 2.3. Composition- and size-dependent absorption and emission. (A) Size- and 
material-dependent emission spectra of several surfactant-coated semiconductor 
nanocrystals in a variety of sizes. The blue series represents different sizes of CdSe 
nanocrystals with diameters of 2.1, 2.4, 3.1, 3.6, and 4.6 nm (from right to left). The 
green series is of InP nanocrystals with diameters of 3.0, 3.5, and 4.6 nm. The red series 
is of InAs nanocrystals with diameters of 2.8, 3.6, 4.6, and 6.0 nm. (B) A true-color 
image of a series of silica-coated core (CdSe)-shell (ZnS or CdS) nanocrystal probes in 
aqueous buffer, all illuminated simultaneously with a handheld ultraviolet lamp. 
 
 6
2.1.2.2. Unique optical spectra. Organic dyes typically have narrow absorption 
spectra, which makes simultaneous excitation difficult in most cases. Furthermore, they 
have asymmetric emission spectra broadened by a red-tail, making quantitation of 
different probes difficult. In contrast, QDs have broad absorption spectra, enabling 
excitation by a wide range of wavelengths, and their emission spectra are symmetric and 
narrow (Figure 2.4.) (Alivisatos et al., 2005; Michalet et al., 2005). Consequently, QDs 




(Michalet et al., 2005) 
Figure 2.4. Absorption and emission spectra of QDs. Absorption (upper curves) and 
emission (lower curves) spectra of four CdSe/ZnS QD samples. The blue vertical line 
indicates the 488-nm line of an argon-ion laser, which can be used to efficiently excite all 
four types of QDs simultaneously. 
 
2.1.2.3. Photostability. QDs have strong photostability due to their inorganic 
composition, making them extremely resistant to photobleaching compared to organic 
dyes (Figure 2.5.). This characteristic makes QDs very attractive probes for continuous 




(Wu et al., 2003) 
Figure 2.5. Photostability comparison between QDs and Alexa 488. Top row: nuclear 
antigens were labeled with QD 630-streptavidin (red), and microtubules were labeled 
with Alexa 488 conjugated to anti-mouse IgG (green) simultaneously in a 3T3 cell. 
Bottom row: microtubules were labeled with QD 630-streptavidin (red), and nuclear 
antigens were stained green with Alexa 488 conjugated to anti-human IgG.  
 
2.1.2.4. Long luminescent lifetimes. Typically, the luminescent lifetimes of 
organic dyes or auto-fluorescent proteins are a few nanoseconds. In contrast, the lifetime 
of QDs is 10 to 40 ns (Alivisatos et al., 2005), which is significantly longer than organic 
dyes. Such long lifetime greatly reduced background noises in live cell imaging. 
Common organic dyes allow singlet–singlet electronic transition in a few nanoseconds. 
Unfortunately, this prompt emission coincides with a high degree of short-lived 
autofluorescence background from many naturally occurring species in a biological 
specimen. Delayed (longlifetime) fluorescence labels for time-gated image and 
fluorescence lifetime imaging have long been sought for enhanced contrast in cellular 
imaging. However, because their fluorescence lifetime is too long, these probes have a 
limited photon turnover rate and therefore limited sensitivity. QDs emits light slowly 
enough that most of the autofluorescence background is over by the time emission occurs 
but fast enough to maintain a high photon turnover rate. Therefore QDs may be ideal 
 
 8
probes for spectrally multiplexed, time-gated cellular detection with enhanced selectivity 
and sensitivity (Dahan  et al., 2001). 
2.1.3. Biological Applications. The first advantage of QDs is their utility as a 
stable fluorescent marker for many purposes, including cancer diagnosis and treatment. 
Wu et al. used QDs linked to streptavidin and antibody to detect the receptor Her2 on 
SK-BR-3 breast cancer cells (Wu et al., 2003). Type II QDs emit light within the NIR 
spectrum and have a potential surgical utility by providing optical guidance that can 
result in reduction of cancer metastases (Soltesz et al., 2006). QD fluorescence can also 
be used for sentinel lymph node (SLN) mapping and removal, which provides accurate 
staging and therapeutic planning (Kim et al., 2004; Parungo et al., 2005a; Parungo et al., 
2005b; Soltesz et al., 2005; Soltesz et al., 2006). QDs properties such as multiplexing 
potential, photostability, and inorganic nature make them useful for drug discovery. For 
example, they allow monitoring of multiple drug candidates over extended time periods 
in cell culture simultaneously, thus saving time and cost (Ozkan, 2004). Lai et al. used 
surface-modified CdS QDs as chemically removable caps to retain drug molecules and 
neurotransmitters inside mesoporous silica nanospheres. The CdS cap ensures the drug is 
inside the system until released by disulfide bond reducing reagents (Lai et al., 2003; 
Alivisatos et al., 2005).  
 
2.2. INTRODUCTION OF CPPs 
CPPs are peptides made of less than 30 amino acids. These CPPs are rich in arginine 
and lysine residues. Positively charged amino acids, hydrophobicity and amphipathicity 
are common features shared among many of the known CPPs. 
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The three most widely studied CPPs are from the human immunodeficiency virus 
type 1 (HIV-1) transcriptional activator Tat protein (Frankel and Pabo, 1988; Green and 
Loewenstein, 1988), the Drosophila homeodomain transcription factor antennapedia 
(Joliot et al., 1991), and the herpes simplex virus structural protein VP22 (Elliott and 
O'Hare, 1997). Derived from HIV Tat peptide, many basic peptides have been generated, 
such as Polyarginines, Pep-1, MPG, pVEC, SAP . These peptides and their variations can 
covalently cross-link or noncovalently interact with a wide variety of biologically active 
molecules up to 200 nm in diameter (Wadia and Dowdy, 2002).  
Due to their low cytotoxicity and ability to carry multiple types of cargo, CPPs have 
been used to improve delivery of many molecules such as small molecules, 
oligonucleotide, plasmid DNA, peptide, protein, nanoparticle, lipid-based formulation, 
virus, quantum dots. The number of applications using CPPs is consistantly increasing, 
and so far more than 300 studies using either covalent or non-covalent CPP-based 
strategies from in vitro to in vivo have been reported (Heitz et al., 2009).  
 
2.3. INTRODUCTION OF ENDOCYTOSIS 
Endocytosis is a basic cellular process that is used by cells to internalize a variety of 
molecules. Endocytosis is the process of internalization of PM, ligands and fluid into the 
cell, which can be divided into two main categories: phagocytosis or pinocytosis. 
Phagocytosis takes place only in professional phagocytes such as macrophages, 
monocytes and neutrophils, while pinocytosis occurs in most mammalian cell types 
(Gong et al., 2008). Therefore, pinocytosis is called generally endocytosis, which can be 
categorized into four different types: macropinocytosis, clathrin-dependent endocytosis, 
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caveolae-dependent endocytosis or clathrin- and caveolae-independent endocytosis  
(Conner and Schmid, 2003; Mayor and Pagano, 2007; Gong et al., 2008) (Figure 2.6.).  
 
 
(Sandvig et al., 2008) 
Figure 2.6. Overview of different types of endocytosis. 
 
2.3.1. Clathrin-dependent Pathway. Clathrin-dependent pathway is the major 
and best characterized endocytic pathway. Clathrin has specific trafficking motifs, 
including the tyrosine-based motif, di-leucine-based motif, NPXY and mono-/multi-
ubiquitination (Mousavi et al., 2004). These trafficking motifs are recognized by various 
adaptor proteins, most notably the adaptor protein 2 (AP-2) (Gong et al., 2008). During 
internalization, the adaptor proteins link the membrane cargo proteins to clathrin, 
concentrating them in clathrin-coated pits. The clathrin-coated pits invaginate into the 
cytoplasm, and eventually pinch off from the plasma membrane to form clathrin-coated 
vesicles (80–120 nm in diameter) (Conner and Schmid, 2003).  
The clathrin-dependent pathway is a highly regulated process. The assembly of the 
clathrin lattice on the membrane is essential for the detachment of the vesicles. Drugs that 
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dissociate clathrin and adaptor protein complex from membrane can inhibit this pathway. 
The small GTPase dynamin is also very important for clathrin-dependent endocytosis 
because it is required to facilitate the fission process (Damke  et al., 1994). Therefore, 
clathrin-dependent endocytosis requires energy. 
2.3.2. Caveolea-dependent Pathway. Caveolae are a special type of lipid rafts. 
Caveolea have a unique morphology of flask-shaped invaginations (50–80 nm in 
diameter) on the cell surface (Conner and Schmid, 2003).  
2.3.2.1. Caveolin-dependent endocytosis. Caveolae contain a high level of 
caveolin proteins, including three caveolin isoforms: caveolin-1, caveolin-2, and 
caveolin-3. Caveolin-1 and caveolin-2 are mainly found in non-muscle cells, while 
caveolin-3 is expressed in skeletal and smooth muscle cells (Parton and Simons, 2007). 
Cholesterol is required for caveolar uptake and drugs that bind to or sequester cholesterol 
perturb internalization of caveolea (Schnitzer  et al., 1994). Caveolar budding requires 
Src-family kinases, dynamin and local actin polymerization (Sverdlov  et al., 2007).  
2.3.2.2. Flotillin-dependent endocytosis. Recent report shows that an alternative 
caveolin-independent mechanism for making caveolae can somehow cause the formation 
of caveolae. Flotillin 1 and flotillin 2 have similar topology to caveolin 1. Overexpression 
of flotillin 1 and flotillin 2 in HeLa cells induced membrane curvatures and formation of 
membrane invaginations morphologically similar to caveolae (Frick et al., 2007). These 
flotillin-positive but caveolin-negative structures might be internalized by “classical” 
caveolae (Frick et al., 2007; Hansen and Nichols, 2009).  
2.3.3. Macropinocytosis. Macropinocytosis refers to the formation of large 
endocytic vesicles of irregular size and shape, generated by actin-driven envagination of 
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the plasma membrane (Swanson and Watts, 1995). A ruffle is formed by a liner band of 
outward-directed actin polymerization near the plasma membrane. The endocytic vesicles 
of macropinocytosis pathway, also known as macropinosomes, are formed through the 
folding back and closure of membrane ruffle structures. Macropinosomes have no coat 
and do not concentrate receptors. Macropinosomes are large vesicles with range from 1 to 
5 µm in diameter (Conner and Schmid, 2003).  
Ruffling is dependent on actin cytoskeleton. Therefore, drugs that disrupt the actin 
cytoskeleton can inhibit macropinocytosis. The ruffling response is also dependent on 
protein kinase C. Macropinocytosis can also be inhibited by amiloride and its analogs, 
which inhibit the Na+/H+ exchange protein in the plasma membrane. Recent studies show 
that macropinocytoiss is lipid-raft dependent process. Therefore, cholesterol depletion 
can inhibit macropinocytosis.  
2.3.4. Clathrin- and Caveolea-independent Pathways. The research on clathrin- 
and cavoelea-independent endocytosis is still at an early stage. So far, there is still no a 
satisfactory classification for those novel pathways. Recently, Mayor and Pagano 
proposed two different classifications. According to the requirement of dynamin, these 
pathways are divided into dynamin-dependent and dynamin-independent mechanism. A 
second division is related to the involvement of small GTPases. Four different types are 
subdivided by RhoA-regulated, cdc42-regulated, and Arf6-regulated endocytic pathway 







3. MATERIAL AND METHODS 
3.1. QUANTUM DOTS 
CdSe/ZnS quantum dots (Adirondack Green, 520nm) were purchased from Evident 
Technologies (Troy, NK, USA). These quantum dots have a PEG lipid surface coated 
with carboxyl terminal groups. The emission and excitation peak wavelengths are 520 nm 
and 505 nm respectively. The hydrodynamic diameter is 25 nm.  
 
3.2. NONA-ARGININES (sR9) 
Nona-arginines were synthesized by solid-phase peptide synthesis (Sigma-Aldrich, 
Saint Louis, MO, USA). The synthesized peptides were purified by high performance 
liquid chromatography (HPLC) using a reverse column. The purity of sR9 was up to 99%.  
 
3.3. CHEMICALS  
Fetal bovine serum, Ham’s F-12 medium with L-glutamine, trypsin-EDTA (1x), 
Penicillin-streptomycin, sucrose, sodium azide, sodium fluoride, and chlorpromazine 
were purchased from Fisher Scientific (Pittsburgh, PA, USA). Nystatin, filipin, 5-(N-
ethyl-N-isopropyl) amirolide (EIPA), Cytochalasin D (Cyt D), antimycin A, and 
monodansylcadaverine (MDC) were obtained from Sigma-Aldrich. 
 
3.4. CELL CULTURE 
The human bronchoalveolar carcinoma-derived cell line (A549) was purchased from 
ATCC (Manassas, VA, USA). Cells were maintained in Ham’s F-12 medium 
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 µg/mL 
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streptomycin, and grown at 37ºC in a 5% CO2 humidified environment. A549 cells were 
seeded into 35 mm glass-bottom tissue culture plates (MatTek, Ashland, MA, USA) at an 
initial confluency of 20%, and allowed to attach for 48 hours.  
 
3.5. GEL RETARDATION ASSAY 
The QD and sR9 complexes were prepared at different molecular ratios (1:10, 1:20, 
1:30 and 1:60) and incubated for 20 min at room temperature to form noncovalent 
binding between sR9 and QDs. These complexes were analyzed by electrophoresis in a 
0.6% agarose gel in 0.5% TAE buffer at 130 voltages for 60 min. The gel was visualized 
by UV light. 
 
3.6. QD UPTAKE WITH sR9 AT DIFFERENT MOLECULAR RATIOS 
To determine the optimal ratio between QD and sR9 for efficient delivery, A549 
cells were incubated with QD/sR9 at different molecular ratios (1:10 to 1:60). The cells 
were washed with ice-cold PBS for six times to remove unbound QD/sR9. Then 
fluorescent image and quantitation were performed. 
 
3.7. CYTOTOXICITY MEASURMENT 
To determine the cytotoxicity of QD/sR9, A549 cells were treated with 12.5, 25, 50, 
100, and 200 nM of QDs for 24 hours. Untreated cells served as a control group. The 
MTS assay (Cell Titer 96® Aqueous One Solution Assay, Promega) was used to 
determine cytotoxicity. Absorbance was measured at 490 nm using a microplate reader 




3.8. QUANTUM DOTS AND sR9 NONCOVALENT BINDING AND  
INTERNALIZATION 
 
QDs were pre-mixed with sR9 peptides at the molecular ratio of 1:20 at room 
temperature for 20 min. Immediately upon removal of medium from A549 cells, the cells 
were treated with the QD/sR9 mixture at a final concentration of 150 nM for QDs for 
designated period of time. After treatment, cells were washed with ice-cold PBS for six 
times. Phenol red free medium (2 mL) (Invitrogen, Carlsbad, CA, USA) was added for 
fluorescent image study.  
 
3.9. UPTAKE STUDIES 
To determine the mechanism of uptake, specific inhibitors of each type of uptake 
pathway were selected. Table 4.1 lists all the inhibitors in our internalization studies.  
3.9.1. Energy Inhibition. To determine whether uptake of QD/sR9 was energy-
dependent, cells were incubated with QD/sR9 under varying metabolic conditions. For 
low temperature studies, cells were treated at either 37ºC or 4ºC. For low temperature 
group, cells were preincubated at 4ºC for 30min, and then cells were treated with QD/sR9 
at 4ºC for another 1 hour. Treatment at 37°C was used as the control group. In metabolic 
inhibition experiments, cells were incubated in the absence or presence of a mixture of 
metabolic inhibitors (0.15% sodium azide, 15 mM sodium fluoride, and 2 µg/mL 
antimycin A). Cells were pretreated with a mixture of metabolic inhibitors for 1 hour 
followed by addition of QD/sR9 to the cells and then incubated for another 1 hour. 
Table 4.1. Inhibitors for mechanistic studies on cellular uptake 
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Inhibitor Effect Mechanism References 
Low 
temperature 
General inhibitor of 
endocytosis 
Energy depletion Vives, Brodin et al. 
1997; Kaplan, Wadia 
et al. 2005 
Metabolic 
inhibitors  
General inhibitor of 
endocytosis 
Energy depletion Almofti, Harashima 
et al. 2003; Khalil, 
Kogure et al. 2006 




and adaptor protein 
complex 2 (AP2) 
Wang, Rothberg et al. 
1993; Yao, Ehrlich et 
al. 2002 

















Hansen, Sandvig et 
al. 1993 
Filipin Inhibitor of lipid-
raft/caveolae 
Cholesterol binding Schnitzer, Oh et al. 
1994; Khalil, Kogure 
et al. 2006 
Nystatin Inhibitor of lipid-
raft/caveolae 
Sequester cholesterol Wadia, Stan et al. 
2004 
EIPA Specific inhibitor 
of 
macropinocytosis 
Inhibits the Na+/H+ 
exchange protein 
Hewlett, Prescott et 
al. 1994 




Cooper 1987; Wadia, 
Stan et al. 2004 
 
3.9.2. Clathrin-dependant Pathway Inhibition. To disrupt clathrin-dependent 
endocytosis, hypertonic challenge, chlorpromazine, and MDC were used. Cells were 
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pretreated with 0.45 M sucrose, 10 µM chlorpromazine, or 25 µg/mL MDC, respectively, 
for 30 min, and then QD/sR9 were added to the cells followed by 1 hour incubation. 
3.9.3. Caveolea-dependant Pathway Inhibition. To inhibit caveolea-dependent 
endocytosis, filipin and nystatin were used to deplete cholesterol. Cells were 
preincubated with 3 µg/mL filipin and 20 µg/mL nystatin, respectively, for 30 min before 
treatment with QD/sR9 for another 1 hour. 
3.9.4. Macropinocytosis Pathway Inhibition. EIPA (30 µM) or Cyt D (1 µg/mL) 
was selected to block macropinocytosis. Cells were pretreated with these inhibitors for 30 
min before treatment with QD/sR9 for another 1 hour. 
3.9.5. siRNA Transfection. Due to potential nonspecific effects and toxicity of 
inhibitors, clathrin heavy chain and caveolin-1 siRNA (Sigma-Aldrich) were used to 
knockdown clathrin and caveolar pathways. The sense and antisense sequences of these 
siRNA are as follows. 
Clathrin HC: 5’-CCCUAAACACCUCAACGAU-3’ (sense) 
          5’-AUCGUUGAGGUGUUUAGGG-3’ (antisense) 
 
Caveolin-1 5’-CAUUAUGACCGGGCUCAUA-3’ (sense) 
         5’-UAUGAGCCCGGUCAUAAUG-3’ (antisense)   
Transfection of siRNA into the A549 cells were performed at a ~30% cell 
confluence. siRNA was complexed with Lipofectamine 2000 reagent according to the 
manufacturer’s instructions (Invitrogen). Western blot and QD/sR9 uptake studies were 
conducted 3 days after transfection. 
 
3.10. WESTERN BLOT ANALYSIS 
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A549 cells were lysed in Lysis buffer (150 mM sodium chloride, 1.0% Triton X-100, 
50 mM Tris, pH 8.0) containing 1% protease inhibitor cocktail (Sigma-Aldrich). The 
protein concentration was quantified by the Bradford procedure (BioRad, Hercules, CA, 
USA). Ten µg total cell protein was electrophoresed on 8% (clathrin-heavy chain) or 
12% (caveolin-1) SDS-PAGE, followed by electrotransferring to a nitrocellulose 
membrane. Clathrin-heavy chain was detected using a mouse monoclonal antibody at a 
dilution of 1:200 and goat anti-mouse IgG-HRP secondary antibody (Santa Cruz, CA, 
USA). Caveolin-1 protein was detected using a rabbit monoclonal antibody at a dilution 
of 1:1000 and goat anti-rabbit IgG-HRP secondary antibody (Cell Signaling, Danvers, 
MA, USA). The blots were probed with the ECL Western blot detection system 
according to the manufacturer’s instructions (Thermo Fisher Scientific, Rockford, IL, 
USA). 
 
3.11. EPIFLUORESCENT MICROSCOPY 
After treatment with QD/sR9, cells were viewed under the Olympus IX51 inverted 
microscope at 600X total magnification using a UPLFLN 60X NA 1.25 objective 
(Olympus, Center Valley, PA, USA). QD filter set (EX 435/40, EM 519-700) was used 
for QDs (Semrock). Images were captured with a Hamamatsu ORCA285 CCD camera. Z 
series images of entire cell volume were taken at 0.3 µm internals. Images were analyzed 
by the SlideBook software (Intelligent Imaging Innovations, Denver, CO, USA). 
 
 
3.12. STATISTICAL ANALYSES 
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Data of fluorescent images were representatives of at least two independent 
experiments. Fluorescent intensity was quantified by using the SlideBook software. Data 
represented mean fluorescence intensity (after background subtraction) of a single plane 
in Z series. One-tailed unpaired Student’s t-test was used for significance testing, using p 
values of 0.01 and 0.05. Data were expressed as the mean ± standard deviation from 10 




4.1. FORMATION OF QD/sR9 NONCOVALENT BINDING 
To test whether sR9 peptide could noncovalently bind to QDs, QDs were mixed 
with sR9 at various molecular ratios (1:10, 1:20, 1:30 and 1:60). These mixtures were 
separated by electrophoresis in a 0.6% agarose gel (Figure 4.1). The QD mobility was 
reduced as the amount of sR9 increased. This result indicated that sR9 peptide interacted 
with QDs and bound non-covalently.  
 
 
Figure 4.1.  Gel retardation analysis of the interaction between QDs and sR9. QDs 
were pre-mixed with sR9 at different molecular ratios. Lane 1 showed QDs without sR9, 
while Lanes 2-5 represented QDs mixed sR9 at ratios of 10, 20, 30 and 60 respectively. 
The mobility was reduced as the amount of sR9 increased. 
 
4.2. MOLECULAR RATIOS BETWEEN QD AND sR9 AFFECT UPTAKE 
To determine the optimal ratio for cellular uptake, A549 cells were incubated with 
QDs (150 nM) preincubated at different molecular ratios with sR9. Figure 4.2 shows that 
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at ratio from 1:10 to 1:30, QD uptake was increased as the ratio of sR9 increased. 
However, when the ratio was above 1: 30, the speed of internalization reached saturation. 
In subsequent studies, we selected 1:20 as interaction ratio between QDs and sR9, 
because this ratio provides good imaging quality.  
 
 
Figure 4.2. QD uptake with sR9 at different molecular ratios. QDs were pre-mixed 
with sR9 at molecular ratios (1:10 to 1:60). A549 cells were treated with QD/sR9. Error 
bars represent the S.D. for 10 different fields performed in two independent experiments. 
Fluorescence intensity is normalized relative to 1:10. 
 
4.3. TIME DEPENDENT UPTAKE 
To determine the optimal dosing time, A549 cells were incubated with QD/sR9 for 5 
min, 20 min, 40 min, 1 hour and 3 hours. Figure 4.3 shows that the uptake of QD/sR9 
 
 22
was dramatically increased after 20 min. At 1 hour, the uptake reached to the peak. Since 
internalization was high at 1 hour, this time point was used for further experiments. 
 
 
Figure 4.3. Time dependent uptake of QD/sR9. QDs were pre-mixed with sR9 at 
molecular ratios (1:20). A549 cells were treated with QD/sR9 for 5 min, 20 min, 40 min, 
1 hour and 3 hour, respectively. Error bars represent the S.D. for 10 different fields 
performed in two independent experiments. Fluorescence intensity is normalized relative 
to 5 min. 
 
4.4. CYTOTOXICITY OF QD/sR9 
To assess potential cytotoxicity caused by QD/sR9 complex, A549 cells were treated 
with QD/sR9 (1:20) complex at various QD concentrations for 24 hours. No cytotoxicity 





Figure 4.4. Cell viability of QD/sR9 treated cells. A549 cells were treated with QD/sR9 
(1:20) for 24 hours. The concentrations of QDs used were: 12.5, 25, 50, 100 and 200 nM. 
The cells treated with QD/sR9 showed a statistically insignificant difference from the 
control group.  
 
4.5. CELLULAR UPTAKE OF QDs FACILITATED BY sR9 PEPTIDE  
To determine the ability of sR9 peptide to facilitate QD delivery, A549 cells were 
treated with 150 nM QDs alone or 150 nM QDs premixed with sR9 at a ratio of 1:20. 
After incubation of 5 min, 20 min, 40 min and 60 min, QDs treated cells were observed 
under epifluorescence microscope. Figure 4.5 shows that the uptake of QD/sR9 was 
statistical significantly increased above QDs alone at all time points. Uptake of the 












Figure 4.5. sR9 facilitate QD uptake. A: the relative fluorescence intensity of QDs. 
A549 cells were treated with 150 nM QD and 150 nM QD/sR9 (1:20) for 5 min, 20 min, 
40 min and 60 min respectively. Error bars represent the S.D. for 10 different fields 
performed in two independent experiments. Significance indicated by: *p < 0.01 vs. QD 
alone group. Fluorescence intensity is normalized relative to QD alone at 5 min. B and C: 
the images of QDs’ uptake with and without sR9 after 1 hour treatment. Images represent 





4.6. MECHANISM OF QD/sR9 INTERNALIZATION 
Endocytosis, an essential cellular process of internalizing extracellular materials, 
utilizes several distinct pathways. To determine the mechanism of sR9-mediated QD 
delivery, a series of inhibition studies were carried out. 
4.6.1. Energy Dependent Studies. To understand whether uptake of QD/sR9 was 
mediated by energy-dependent endocytosis, we used low temperature or a mixture of 
metabolic inhibitors to deplete intracellular energy. For the low temperature study, the 
cells were incubated with QD/sR9 at 37°C and 4°C respectively. As shown in Figure 4.6b, 
QD/sR9 internalization at 4°C was significantly impeded. Compared to 37°C, the 
fluorescence intensity at 4°C decreased by 72% (p’s < 0.01). In the metabolic inhibition 
study, A549 cells were incubated with QD/sR9 in the presence or absence of a mixture of 
metabolic inhibitors (0.15% sodium azide, 15mM sodium fluoride, and 2µg/ml antimycin 
A). As shown in Figure 4.6c, these metabolic inhibitors strongly inhibited the uptake of 
QD/sR9. In comparison with the control group, the fluorescent intensity in the presence 












Figure 4.6. Energy inhibition reduced QD/sR9 internalization. A: the images of 
control cells. B: the images of cells pre-treated at 4°C for 30 min, then incubated with 
QD/sR9 for additional 1 hour. C: the images of cells pre-treated with metabolic inhibitor 
mixture for 1 hour, then incubated with QD/sR9 for additional 1 hour. Images represent 
single plane of Z series. D: mean fluorescence intensity. Error bars represent the S.D. for 
10 different fields performed in two independent experiments. Significance indicated by: 







4.6.2. Clathrin-dependent Pathway. To perturb the clathin-dependent uptake 
pathway, three methods were used:  MDC, hyperotonic sucrose, and chlorpromazine. The 
inhibitory activity of MDC is attributed to the stabilization of nascent clathrin-coated 
vesicles, which limit new clathrin-coated vesicle production (Phonphok and Rosenthal, 
1991). The underlying mechanism of hypertonic sucrose involves the dispersion of 
clathrin lattices on the plasma membrane (Hansen et al., 1993). Chlorpromazine is a 
cationic amphipathic drug that relocates clathrin and adaptor protein complex 2 (AP2) 
from plasma membrane to endosomal membrane (Wang et al., 1993). MDC reduced the 
uptake of QD/sR9 by 45% while hypertonic medium decreased uptake by 59% (data not 
shown). Contrarily, chlorpromazine did not result in significant uptake reduction 
compared to the control group (Figure 4.7).  
4.6.3. Lipid-raft/Caveolea-dependent Pathway. Nystatin and filipin, lipid raft 
inhibitors, are used to block caveolea-dependent endocytic pathway (Schnitzer et al., 
1994; Wadia et al., 2004). Treatment of cells with these two inhibitors moderately 
reduced the QD/sR9 internalization by 36% and 35%, respectively (Figure 4.8) indicating 










Figure 4.7. Two different clathrin inhibitors produced different effects on QD/sR9 
internalization. A: the images of control cells. B: the images of cells pre-treated with 
chlorpromazine for 30 min, then incubated with QD/sR9 for additional 1 hour. C: the 
images of cells pre-treated with MDC for 30 min, then incubated with QD/sR9 for 
additional 1 hour. Images represent single plane of Z series. D: mean fluorescence 
intensity. Error bars represent the S.D. for 10 different fields performed in two 









Figure 4.8. Lipid raft/Caveolea inhibition decreased QD/sR9 internalization. A: the 
images of control cells. B: the images of cells pre-treated with nystatin for 30 min, then 
incubated with QD/sR9 for additional 1 hour. C: the images of cells pre-treated with 
filipin for 30 min, then incubated with QD/sR9 for additional 1 hour. Images represent 
single plane of Z series. D: mean fluorescence intensity. Error bars represent the S.D. for 
10 different fields performed in two independent experiments. Significance indicated by: 
*p < 0.01 vs. control. 
 
4.6.4. Macropinocytosis Pathway. EIPA is an inhibitor of Na+/H+ exchange 
required for macropinocytosis (Hewlett et al., 1994). Cytochalasin D (Cyt D) is an F-
actin depolymerizing drug that caps the barbed or faster-growing ends of actin filaments 
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(Cooper, 1987). The use of EIPA inhibited the uptake of QD/sR9 by 54% (Figure 4.9). 
To confirm the effective concentration of Cyt D, we used Alexa 568 - phalloidin to stain 
actin of Cyt D treated and control cells. At 1µg/ml, actin was successfully depolymerized 
in A549 cells (data not shown). Cyt D reduced the uptake of QD by 11% (Figure 4.9). 
Significant amount of condensed green fluorescent agglomerates were observed around 





Figure 4.9. Macropinocytosis inhibition perturbed QD/sR9 internalization. A: the 
images of control cells. B: the images of cells pre-treated with EIPA for 30 min, then 
incubated with QD/sR9 for additional 1 hour. C: the images of cells pre-treated with Cyt 
D for 30 min, then incubated with QD/sR9 for additional 1 hour. Images represent single 
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plane of Z series. D: mean fluorescence intensity. Error bars represent the S.D. for 10 
different fields performed in two independent experiments. Significance indicated by: *p 
< 0.01 vs. control. 
 
4.6.5. siRNA Knockdown. Considering potential nonspecific inhibition and 
cytotoxicity of inhibitors, we further used the RNAi techniques to confirm the uptake 
mechanisms. Clathrin HC and caveolin-1 siRNA were used to knockdown clathrin-
dependent and caveolin-depedent pathway, respectively. Western blot demonstrated the 
success of knockdown clathrin and caveolin-1 protein expression (Figure 4.10). In the 
clathrin HC or caveolin-1 protein knockdown cells, the uptake of QD/sR9 was not 
affected significantly (Figure 4.11). Clathrin siRNA data was in agreement with 
chlorpromazine, which indicated that the uptake was not clathrin-dependent endocytosis. 
Caveolin-1 siRNA data demonstrated that the caveolin-dependent pathway was not 
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Figure 4.10. Western blot analysis. A549 cells were treated with siRNA of clathrin HC 
and caveolin-1 protein for 3 days, and then cells were lysed for western blot analysis. A: 
clathrin HC protein expression in A549 cells. B: caveolin-1 protein expression in A549 








Figure 4.11. QD/sR9 uptake after knockdown of clathrin HC and caveolin-1 protein. 
A549 cells were treated with siRNA of clathrin HC and caveolin-1 protein for 3 days, and 
then cells were used for uptake studies. A: the images of control cells. B: the images of 
cells pre-treated with clathrin HC siRNA. C: the images of cells pre-treated with 
caveolin-1 siRNA. Images represent single plane of Z series. D: mean fluorescence 
intensity. Error bars represent the S.D. for 5 different fields performed in two 






Quantum dots are emerging as a new class of fluorescent probe for cellular imaging. 
In comparison with organic dyes and fluorescent proteins, QDs have unique properties, 
such as high quantum yield and photostability which make them better suited for 
delivering and monitoring biomolecules. However, studies have shown that QDs are 
slowly internalized into the cell. Our goal was to test whether nona-arginine (sR9) can 
facilitate QD uptake and the mechanism of the uptake. Data from this study demonstrate 
that QDs are rapidly internalized into A549 cells within 5 min with the aid of sR9 (data 
not shown) while without the presence of sR9 QDs uptake is minimal. The enhancement 
of internalization is thought to be due to an electrostatic interaction between cationic 
nona-arginine and the negatively charged polar heads of the phospholipids of the plasma 
membrane (Snyder and Dowdy, 2004). Our study demonstrates that sR9 increased QD 
uptake up to 200nM without incurring toxicity.   
QD/sR9 are internalized by endocytosis. In live cells, QD/sR9 internalization was 
dramatically blocked by either low temperature or a mixture of metabolic inhibitors. This 
indicated that the uptake of QD/sR9 was highly energy-dependent and supported that 
endocytosis was a major uptake process. Subsequent studies were conducted to further 
understand specific pathways of endocytosis. 
Clathrin-dependent endocytosis is a well-characterized endocytic pathway. Treating 
cells with hypertonic sucrose significantly reduced QD/sR9 uptake. Although this kind of 
blockage is considered strong evidence of clathrin-dependent endocytosis, recent studies 
have shown that it also interferes with other internalization pathways, such as caveolea-
dependent endocytosis and macropinocytosis (Ivanov, 2007). Thus, two specific 
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inhibitors, chlorpromazine and MDC, were selected for further investigation. Our data 
showed that MDC effectively impeded QD/sR9 internalization, while chlorpromazine at 
the highest possible nontoxic concentration exhibited no inhibition of QD/sR9 uptake. 
This contradiction might arise from two possibilities: 1) insufficient concentration of 
chlorpromazine; or 2) blockage of other internalization pathways by MDC. The former 
cannot be overcome due to apparent cytotoxicity. Blockage of other pathways by MDC 
treated cells might account for the possible explanation of the discrepancy. It is known 
that MDC is also an inhibitor of the transglutaminase family, which activates Rho 
GTPases, the key regulators of actin assembly and dynamics (Ivanov, 2007). Thus, MDC 
might block actin dependent pathways such as macropinocytosis. Because of these 
limitations of the inhibitor studies, we adopted siRNA to knockdown the clathrin 
pathway. The Western blot analysis indicated a complete knowdown of clathrin protein. 
The QD fluorescence intensity inside cells did not differ from the control cells indicating 
that clathrin-dependent pathway was not involved in QD/sR9 internalization.  
Nystatin and filipin are polyene antibiotics, which create large aggregates 
accumulating cholesterol and thereby sequester lipid from cell membranes. Nystatin and 
filipin are highly selective inhibitors of the lipid raft dependent pathway because of lipid 
sequestering. Our data showed that both inhibitors hindered the uptake of QD/sR9, 
suggesting that the internalization was lipid raft dependent. Cholesterol depletion could 
result in blockage of several lipid raft dependent endocytic pathways, including caveolae-
dependent and macropinocytosis pathways (Wadia et al., 2004). For further distinction, 
caveolin-1 siRNA was chosen to knockdown caveolin-dependent pathway. The Western 
blot analysis indicated a near complete knockdown of caveolin. However, live cell 
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imaging indicated no reduction of QD/sR9 internalization indicating a caveolin-
independent pathway of QD/sR9 internalization. Collectively, QD/sR9 internalization 
occurred through a lipid raft dependent process, but was not mediated by clathrin and 
caveolin.  
Macropinocytosis is a rapid, lipid raft-dependent and receptor-independent form of 
endocytosis. Macropinocytosis includes three essential steps: actin cytoskeleton-driven 
ruffle formation, closure of the ruffle into a vesicle, and dissociation of actin filaments 
from the vesicle (Swanson and Watts, 1995). The fluorescent intensities in cells treated 
with two macropinocytosis inhibitors, EIPA and Cyt D, were significantly reduced, 
compared to the control cells. It is worth noting that QD/sR9 was densely localized 
around cellular surfaces, not in cytosol. Nakase et al. observed a similar phenomenon that 
cellular R8 peptide was predominantly localized in cellular boundaries and very little 
punctuate staining was observed in Cyt D treated cells (Nakase et al., 2004). Ruan et al. 
also had the similar observation (Ruan et al., 2007). It is unclear how the dense 
aggregates affect quantitation. Further, the mechanism of the entrapment in plasma 
membranes remains to be investigated.  
Collectively, our data show that sR9 can facilitate rapid cellular entry of QDs. The 
process requires energy. Chathrin and Calveolin-1 are not mediators of internalization. 
The major mechanism involves lipid raft and depends on macropinocytosis. Uptake 
mechanisms other than clathrin, caveolea, and macropinocytosis may also be involved 
and remain to be investigated. For instance, Rho family is the regulators of RhoA 




6. FUTURE WORK 
In this study, the uptake mechanism of QD/sR9 was carried out. Future work will 
involve several areas, including further uptake mechanism study, modifying uptake 
system and organelle targeting. 
 
6.1. OTHER UPTAKE PATHWAYS 
Three main pathways of endocytosis have been investigated– clathrin-dependent 
endocytosis, caveolea-dependent endocytosis, and macropinocytosis. Next other less-well 
studies pathways will be focused on. Data show that QD/sR9 uptake can be inhibited by 
MDC, which can block actin-dependent endocytosis via Rho family inhibition. Therefore, 
other pathways involved Rho family could affect QD/sR9 uptake, such as Rho A 
dependent pathway, CDC 42 dependent pathway.  
 
6.2. ENDOSOMAL ESCAPING 
Data show that QD/sR9 was entrapped in endosome (not shown), which will reduce 
the function of cargoes. Therefore, endosomal escaping is the problem that we need to 
resolve before we put cargoes into this delivery system. One method is using pH sensitive 
peptide – HA2. The α-helix of HA2 can insert into endosome membranes at low pH 
value, and then disrupt endosome membrane, which help QD/sR release from endosomes. 
The other method is modifying the surface of QDs by using PEI, which can cause proton 





6.3. ORGANELLE TARGETING 
After endosomal entrapment revolved, organelle targeting will be carried out. 
Because most drugs target nucleus or mitochondria, nucleus localizing signal or 
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